Navigation Links
Marshall Edwards Announces First Patient Dosed in Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Date:9/19/2011

SAN DIEGO, Sept. 19, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that the first patient was dosed in the Company's Phase I clinical trial of its lead drug candidate ME-143 in patients with refractory solid tumors. The trial, conducted in collaboration with the Sarah Cannon Research Institute, is expected to enroll up to 24 patients with final data collected by the second quarter of 2012.

Fiscal Year End Conference Call

Marshall Edwards also announced that its management team will host a conference call with simultaneous webcast on Thursday, September 29, 2011, beginning at 5:00 p.m. Eastern time. Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present an overview of the Company; Robert Mass, MD, Chief Medical Officer, will discuss the Company's lead oncology drug candidates, including an update on the Phase I clinical trial of ME-143; and Thomas Zech, Chief Financial Officer, will provide a summary of the Company's fiscal year ended June 30, 2011 financial results.

To access the live call, please dial 866-800-8652 (toll-free) or 617-614-2705 (international), participant passcode 14784577. A replay of the call will be available approximately two hours after the conclusion of the call. To access the replay, please dial 888-286-8010 (toll-free) or 617-801-6888 (international), passcode 99793585. The conference call will also be webcast live and can be accessed at www.marshalledwardsinc.com/investor. Please connect several minutes prior to the start of the webcast to ensure adequate time for any software downloads that may be required.

About the Phase I Clinical Trial of ME-143

The Phase I trial of ME-143 was initiated earlier
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
2. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
3. Marshall Edwards to Host Annual Meeting of Stockholders
4. Marshall Edwards Receives Positive Response From NASDAQ
5. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
6. Marshall Edwards Announces Private Placement
7. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
8. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
9. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
10. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
11. Marshall Edwards Announces Initiation of Phase I Clinical Trial of Lead Oncology Drug Candidate ME-143
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014   Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... scheduled to present at the Biotech Showcase™ 2015 taking ... on January 12-14, 2015. Michael ... Creek Pharmaceuticals, will present preclinical and clinical data for ... anti-inflammatory pharmacological characteristics. Dr. Mullan will outline the Company,s ...
(Date:11/21/2014)... , 21. November 2014 ... heute bekannt gegeben, dass die Europäische ... die Kennzeichnung als Orphan-Medizinprodukt an Palovarotene ... Unternehmens zur Behandlung von Fibrodysplasia ossificans ... stark beeinträchtigende genetische Krankheit, die von ...
(Date:11/21/2014)... N.J. , Nov. 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: ... Krakauer , Chief Executive Officer, will be presenting at the ... New York Palace Hotel in New York ... 2014 at 2:00 PM ET. In addition, Mr. Krakauer and ... available for separate one-on-one meetings during the day. ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... March 17, 2011 A recently issued patent ... award winning and best selling medical thermometer brand, ... recently been granted U.S. Patent No. 7,787,938, entitled, ... and Trademark Office, adding to the already extensive ...
... VEGAS, March 17, 2011 A new study by Craig ... and North Cypress Medical Center in Houston, presented this week ... the improved photon sensitivity of new detector technologies such as ... dose patient receive from BSGI/MBI studies by 75%.  However, low ...
Cached Medicine Technology:Exergen Granted New Patent for Temporal Artery Thermometers 2New Technologies Open the Door for Low Dose Breast-Specific Gamma Imaging (BSGI) / Molecular Breast Imaging (MBI) 2
(Date:11/22/2014)... November 22, 2014 Recently, UWDress.com is ... wedding guest dresses . In addition, the company has ... , As a leading online supplier of wedding ... beautiful outfits. The unusual best wedding guest gowns are ... the amazing designs, this new selection is famous for ...
(Date:11/22/2014)... Calif. (PRWEB) November 22, 2014 ... applications was announced today which safely detects and ... high frequency radio waves. Developed by RHT SpectraSafe, ... and hosts broad applications in other areas including ... to security. , Using high frequency radio waves ...
(Date:11/22/2014)... A Xarelto lawsuit has been filed on behalf ... million in damages from the makers and marketers of the ... the woman began using Xarelto in March 2012 and used ... she suffered life-threatening bleeding in July 2012 and as a ... emotional distress. The lawsuit purports that the woman’s injuries are ...
(Date:11/22/2014)... HealthDay Reporter FRIDAY, Nov. 21, ... are treated in an ambulance by a neurologist equipped with ... The sooner patients get the clot dissolver -- tissue plasminogen ... the researchers noted. For the best outcome, the drug needs ... start, the researchers said. "The so-called ,golden hour, is ...
(Date:11/21/2014)... November 21, 2014 Porcelain veneer ... smiles for patients in preparation for the coming holiday ... fronts of teeth, look completely natural, and can be ... veneers are also valued for their ability to strengthen ... can be used on one or several teeth to ...
Breaking Medicine News(10 mins):Health News:Best Wedding Guest dresses Introduced by UWDress.com 2Health News:RHT SpectraSafe announces a Radical New Airport Security Technology that Is More Effective, Less Invasive 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 2Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 3Health News:Xarelto Lawsuit News: Woman Seeks $10 Million in Damages For Alleged Bleeding Side-Effect Due To Xarelto Use 4Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 2Health News:Special Ambulance Delivers Vital Stroke Care More Quickly 3Health News:Los Angeles Porcelain Veneers Dentist, Dr. Kevin Sands, Now Creates Picture-Perfect Smiles for Patients for the Holiday Season 2
... Inc. (Nasdaq: LMAT ) announced today that it ... 30, 2008, after the close of the,market. In conjunction ... same day at 5:00 PM ET. The call will ... listen to the live webcast at, http://www.lemaitre.com/investor, or ...
... 18 Dr. James B.,Peake, the Secretary of ... open a unique vocational counseling center for disabled,veterans., ... this center is yet,another partnership that recognizes the ... and access to resources to veterans sets,the stage ...
... BlueCross BlueShield of South,Carolina today announced that Greenville businesswoman ... A native of Elberton, Ga., Shaw now lives ... Corp., a family investment corporation.,She previously worked for C ... National,Bank of South Carolina, and Manly Investment Group in ...
... destination for quality skincare,will debut three new locations ... SEATTLE, April 18 Calidora Skin Clinic, ... its doors,in Southern California this April. The three ... Monica - will offer Southern Californians the,chance to ...
... been proved, one expert says , , FRIDAY, April 18 (HealthDay ... severe psoriasis appears to be safe and effective, a Canadian ... which is a calcineurin inhibitor, significantly improve symptoms of psoriasis. ... is the first oral medication in 20 years to show ...
... (OTC,Bulletin Board: CHRX, CHRXU, CHRXW), a leading provider of ... has,changed to CHRX from PMQC. The Company,s common stock ... About Chem Rx Corporation, Founded more than ... of institutional pharmacy services in the New York City,metropolitan ...
Cached Medicine News:Health News:Disabled Counseling Center Comes to Twin Cities 2Health News:Shaw Elected to S.C. BlueCross BlueShield Board 2Health News:Upscale Seattle-Based Skincare Clinic Expands Into California With Unique Custom Tailored Skincare Approach 2Health News:New Psoriasis Pill Appears Effective 2Health News:New Psoriasis Pill Appears Effective 3Health News:Chem Rx Corporation Changes Ticker Symbol to CHRX 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
Medicine Products: